Home › Targets › P4HTM
Radioligand therapy target profile

P4HTM: IHC Expression in Cancer and Radioligand Target Profile

prolyl 4-hydroxylase, transmembrane · Ensembl ENSG00000178467 · Data updated 2026-11-01

P4HTM, prolyl 4-hydroxylase, transmembrane, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, P4HTM staining is highest in head and neck cancer (100% of samples positive), endometrial cancer (100% of samples positive) and breast cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).

Is P4HTM the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze P4HTM free
LocalizationCell-Surface
Top cancer (IHC)Head and Neck Cancer
InternalizationNot assessed
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.23

Is P4HTM a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

P4HTM IHC staining by cancer type

Protein expression of P4HTM across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Head and Neck Cancer1.00High100%
Endometrial Cancer0.94High100%
Breast Cancer0.92High100%
Glioma0.88High100%
Liver Cancer0.87High100%
Skin Cancer0.86High100%
Melanoma0.86High100%
Lung Cancer0.85High100%
Colorectal Cancer0.83High100%
Thyroid Cancer0.83High100%
Pancreatic Cancer0.82High100%
Ovarian Cancer0.81High100%
Cervical Cancer0.80High100%
Gastric Cancer0.80High100%
Bladder Cancer0.78High100%
Neuroendocrine Tumors0.75High100%
Prostate Cancer0.67High89%
Lymphoma0.56High75%
Testicular Cancer0.50Medium100%
Kidney Cancer0.25Medium50%

Is P4HTM internalized?

Nuclens has not yet extracted internalization evidence for P4HTM. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

P4HTM clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for P4HTM yet. Search ClinicalTrials.gov for P4HTM trials.

P4HTM normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See P4HTM in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

P4HTM gene essentiality (DepMap)

CRISPR knockout effect across 1258 cancer cell lines: -0.14 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related head and neck cancer radioligand targets

EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · SSTR2 · B7-H3 (CD276) · STEAP2 · HER2 (ERBB2)

See all radioligand therapy targets in head and neck cancer.

See how P4HTM ranks against 15,000 targets for your indication.

Analyze P4HTM free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is P4HTM the right target for your program? · 5 free analyses, no card Analyze P4HTM free